eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
12.01
-0.19 (-1.56%)
At close: Dec 19, 2025, 4:00 PM EST
12.30
+0.29 (2.41%)
After-hours: Dec 19, 2025, 4:04 PM EST
eXoZymes Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
31
Market Cap
103.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.07K | 41.47K | 145.01% |
| Dec 31, 2022 | 28.60K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEXOZ News
- 9 days ago - eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion - Accesswire
- 5 weeks ago - eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today - Accesswire
- 5 weeks ago - eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff - Accesswire
- 5 weeks ago - eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST - Accesswire
- 7 weeks ago - CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference - Accesswire
- 7 weeks ago - CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference - Accesswire
- 2 months ago - CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference - Accesswire
- 2 months ago - Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees - Accesswire